AN INTERVENTIONAL CLINICAL TRIAL TO MAKE COMPARISON OF ANTI-INFLAMMATORY EFFECTS OF GLIMEPIRIDE AND SITAGLIPTIN IN OBESE PATIENTS OF TYPE-2 DIABETES

Study Aim: We conducted this study to make comparison of anti-inflammatory effects of glimepiride and sitagliptin in overweight patients of type-2 diabetes. Study design: An Interventional Clinical Trial. Place and duration: This study was carried out for the duration of six months starting from August, 2018 February, 2019 at Holy Family Hospital, Rawalpindi. Material and methodology: We included a total of 110 overweight patients of type-2 diabetes. There were 70 (63.64%) males and 40 (36.36%) females. Randomly divided them into two groups as group-A and group-B. Sitagliptin 50mg was given to group-A while glimepiride 2mg was given to group-B for a time period of three months. Determined the dose corresponding to sugar level of blood. Measured the changes in C-reactive Protein (CRP) as primary results. Whereas, changes in lipid profile, HbA1C, blood sugar level and BMI were recorded as secondary results. Analysis of data was carried out through SPSS 20. Results: All selected patients (110) were divided into two equal groups A and B. At the end of three months treatment HbA1C and blood sugar were found reduced but comparison results among both groups was non-significant with P value equal to 0.59 in group A and 0.17 in group B. Weight of body was slightly increased in group B using glimepiride. On the other hand, in group A using sitagliptin observed slight reduction in body mass. However, comparison of both groups was found non-significant with P value equal to 0.07. significant improvement observed in lipid profile of group A compared to group B that is ) HDL-cholesterol (-2.6 +/- 6.2 A) vs (B 1.2 +/- 5.2) with P-value=0.03, LDL- cholesterol (-10 +/- 22.4 A) vs (B -0.8 +/- 18.7) with P-value=0.001, triglycerides (-19 +/- 44.6 A) vs (B -1.8 +/- 48.7) with P-value=0.001 and total cholesterol (-25 +/- 32.5 A) vs (B +1.5 +/- 45.4) with P-value=0.02. Significant reduction observed in CRP level during comparison of sitagliptin vs glimepiride as (-2.3 +/- 1.8 A) vs (B 0.8 +/- 1.5) with P-value=0.001. Conclusion: In this study we observed that sitagliptin have strong anti-inflammatory effects as noticed via decrease in CRP levels in overweight patients of type 2 diabetes when compared with glimepiride. Sitagliptin also showed positive effects on lipid profiles and glycemic control.